p53

Bcl-2 or Bcl-XL inhibitor

Roslin-2 (Benzylhexamethylenetetramine bromide) is a p53 reactivator with anticancer effects. Roslin-2 binds FAK, disrupts the binding of FAK and p53.

A thymidylate kinase inhibitor

MX69 is an inhibitor of MDM2/XIAP, used for cancer treatment.

NVP-HDM201 (NVP-HDM201) is a potent, orally bioavailable and highly specific p53-MDM2 interaction inhibitor.

RO8994 is a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitor, with IC50 of 5 nM (HTRF binding assays) and 20 nM (MTT proliferation assays).

WR-1065 dihydrochloride can protect normal tissues from the toxic effects of certain cancer drugs and activate p53 through a JNK-dependent signaling pathway.

Poly-L-lysine (M.W 70000~150000) is a polymer consists of numerous L-lysine with great biocompatibility.

Poly-L-lysine hydrobromide (MW 150000-300000) is a high-molecular-weight, positively charged synthetic polypeptide widely used to enhance cell adhesion to culture surfaces. Poly-L-lysine hydrobromide exhibits excellent water solubility and biocompatibility and serves as an essential reagent for the culture of primary neurons, epithelial cells, and stem cells.

Poly-L-lysine (3~7W) is a positively charged synthetic polypeptide polymerized from L-lysine.

Brigimadlin is an orally active MDM2-p53 antagonist. Brigimadlin restores wild-type p53 function by blocking the MDM2-p53 interaction, thereby inducing tumor cell cycle arrest or apoptosis.

Milademetan (DS-3032) (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis.

CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system.

Kevetrin hydrochloride (4-Isothioureidobutyronitrile hydrochloride) is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells.

PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes p53 via selective alkylation of two surface-exposed cysteines without compromising its DNA binding activity. PK11007 induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels.

AM-8735 is a potent and selective MDM2 inhibitor with an IC50 of 25 nM.

DPBQ activates p53 and triggers apoptosis in a polyploid-specific manner, but does not inhibit topoisomerase or bind DNA. DPBQ elicits expression and phosphorylation of p53 and this effect is specific to tetraploid cells.

APG-115 (APG-115) is an orally active MDM2 protein inhibitor binding to MDM2 protein with IC50 and Ki values of 3.8 nM and 1 nM, respectively. APG-115 blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner.

BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC50 of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis.

MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity.

NVP-CGM097 sulfate is a potent and selective MDM2 inhibitor with IC50 of 1.7±0.1 nM for hMDM2.

p53 and MDM2 proteins-interaction-inhibitor chiral (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

p53 and MDM2 proteins-interaction-inhibitor racemic (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.